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Background: Mucopolysaccharidoses (MPS) are chronic progressive lysosomal 
disorders (Six distinct types) which are inherited as autosomal recessive except 
MPS II which is inherited as X-linked recessive disorder
Patients and Methods: This study is designed to investigate a group of  Egyptian 
patients with MPS biochemically using screening test by electrophoretic 
separation of glycosaminoglycans and enzymatic assay in order to establish 
the diagnosis of the disorder and its subtypes, to prepare patients for enzyme 
replacement therapy. Also this will help in proper genetic counseling and 
prenatal diagnosis. Establishing a reliable rapid screening test for MPS is 
another aim of the study. The present study included 20 index cases suspected 
clinically as mucopolysaccardioses at the Medical Genetics Center, Ain Shams 
University (ASUMGC).They were subjected to full history taking, thorough 
clinical examination, family pedigree construction, skeletal survey, abdominal 
ultrasound and echocardiography, quatitative assay of glycosaminoglycans 
(GAGs) by diemethylmethlene blue (DMB) is done. 
results: The level of urinary GAGs by two dimentional electrophoresis (DMB) 
test was high in all patients tested. After that the patients were subjected to 
2-DEP to determine the pattern of GAGs for probable type of MPS. 11 cases 
(55%) showed big dermatan sulfate spot (Type I, II or VI). Seven cases (35%) 
showed hepran sulfate spot (Type III), 2 cases (10%) showed keratan sulfate 
spot (Type IV). Finally patients were subjected to enzyme analysis specific 
for each type of MPS to confirm diagnosis. Reaching a specific diagnosis is of 
importance for genetic counseling and prenatal diognosis which is possible for 
all types of MPS.
conclusion: Prenatal diagnosis was done by 2-DEP of the amniotic fluid for 
four mothers of affected patients of MPS. One fetus was proved to be affected 
with MPS III. Another fetus was affected with MPSII. The others fetuses were 
normal.
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introduction                                                          
The mucopolysaccharidoses (MPS) are 
a group of heritable disorders each of 
which is produced by a deficiency of 
an enzyme required for the lysosomal 
degradation of sulfated glycosamino-
glycans.1
Mucopolysaccharides (or glycosamin-
oglycans) are large macromolecules 
composed of repeating frequently sul-
fated, disaccharide units attached to a 
protein core. A series of lysosomal acid 
hydrolases degrades the glycosamino-
glycans by step-wise removal of the 
sulfates and carbohydrate residues.1
There are 10 known enzyme deficiency 
that give rise to six distinct MPS. Most 
of these enzymes have been extensive-
ly purified, their biosynthesis and pro-
cessing have been elucidated and their 
primary structure determined from the 
sequence of the corresponding cDNA. 
MPS I (Hurler, Hurler-Scheie, Scheie) 
is due to deficiency of lysosmal hydro-
lase, α-l-iduronidase. In MPS II (Hunt-
er  syndrome) the deficient enzyme is 
iduronate sulphatase. As regards MPS 
III (Sanfilippo syndrome, subtypes A, 
B, C and D) is due to deficiency of 4 
enzymes, heparan–N–sulfatase, α–N–
acetyl glucosaminidase, acetyl trans-
ferase, α–N–acetyl glucosamine–6–sul-
fatase). MPS IV (Morquio syndrome, A 
& B subtypes ) is due to deficiency of 
2 enzymes, N–acetylgalactosamine–6–
sulfatase and B–galactosidase. MPS VI 
(Marteaux-Lamy Syndrome) is due to 
deficiency of N-acetylgalactosamine- 
4-sulfatase (Aryl sulphatase). MPS VII 
(Sly syndrome) is due to deficiency of 
β–glucuronidase. MPS IX is due to de-
ficiency of hyluronidase.2 
Clinical symptoms eventually result 
from the lysosomal storage of the par-
tially degraded glycosaminoglycans.3
Incompletely degraded glycosamino-
glycans accumulate in multiple organ 
systems leading to progressive worsen-
ing of the clinical manifestation. MPS 
share many clinical features, though in 
variable degrees. These include a chron-
ic and progressive course, multisystem 
involvement, organomegaly, dystosis 
multiplex and abnormal facies. There 
is clinical similarity between different 
enzyme deficiencies and conversely a 
wide spectrum of clinical severity with-
in any one enzyme deficiency.2
Disorders that result in heparan sulfate 
storage have progressive central ner-
vous system involvement. Affected pa-
tients may have macrocephaly and de-
velop communicating hydrocephalus. 
Dermatan sulfate storage is associated 
with progressive visceral and bone in-
volvement. Affected patients  may have 
hepatosplenomegaly, cardiomyopathy 
or cardiac valvular involvement.2
The first line to diagnose MPS is the 
quantitative assay of excessive uri-
nary GAGs by diemethylmethlene blue 
(DMB) test and qualitative assay of uri-
nary GAGs by two-dimensional elec-
trophoresis (2-DEP) to determine the 
probale MPS type. Definite diagnosis is 
established by enzyme assay. Because 
lysosomal enzymes are present in all 
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cells except mature erythrocytes, the 
deficiency can be determined in a vari-
ety of cells and body fluids. Cultured fi-
broblasts, leukocytes or serum are gen-
erally used. The choice depends on the 
particular enzyme.1
Also the 2-DEP is applicable for pre-
natal diagnosis after amniocentesis and 
enzymatic assay in the fetus is done for 
chrionic villus biopsy specimen.1
aiM of the WorK                                  
This study was designed to investigate 
the  profile  of  a  group of Egyptian 
patients with mucopolysaccharidoses 
(MPS) and its subtypes, to prepare pa-
tients for enzyme replacement therapy. 
This will help in proper genetic counsel-
ing and prenatal diagnosis. Establishing 
a reliable rapid screening test for MPS 
is another aim of the study.
PatientS and MethodS                            
Twenty cases suspected clinically to 
be one of the mucopolysaccharidoses 
syndrome were enrolled in the current 
study. They were chosen from cases 
attending the Medical Genetics Center 
Out-Patient Clinic, Ain Shams Univer-
sity. They were subjected to the follow-
ing:
Full history taking:•	  Lying stress on 
personal history, main complaint, 
developmental history, past history, 
family history of similar condition 
and parental consanguinity. His-
tory of symptoms suggestive of all 
body system involvement will be 
explored.
Thorough clinical examination: •	
including anthropometric  measure-
ments. Ocular, cardiovaslar, abdominal 
and neurological  examinations were 
also done.
Three generations family pedigree •	
constructions: Illustrating paretnal 
consanguinity if any and similar 
condition among family members.
Skeletal survey including:•	  Plain 
x–ray of the skeleton (Skull, upper 
limbs, lower limbs, chest, cervical 
and dorsolumbar spines) to docu-
ment the presence of any skeletal 
abnormalities suggestive of MPS.
Ophthamological examination in-• 
cluding slit lamp examination to 
detect the corneal clouding or other 
abnormalities of the anterior cham-
ber & fundus examination. 
Echocardiography:•	  To document 
any cardiac pathology (Valvular 
involvement and or cardiomyopa-
thy).
Abdominal ultrasonogrphy:•	  To 
document any organomegaly.
Determination of total urinary gly-•	
cosaminoglycans (GAGs):4 Gly-
cosaminoglycans (GAGs) were 
determined quantitatively by reac-
tion with dimethylmethylene blue 
(DMB) in a reaction that didn’t 
require prior precipitation of the 
GAGs. The color was measured 
immediately at a wave length of 
520nm. The DMB ratio was ob-
tained by dividing the urine crea-
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no % no % no % no % no % no % no % no %
      IH 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10
I     IHS 2 10 3 15 2 10 2 10 3 15 3 15 2 10 2 10
IS 0 0 1 5 1 5 0 0 0 0 0 0 0 0 1 5
II 2 10 2 10 0 0 1 5 2 10 2 10 2 10 2 10
III 7 35 5 25 0 0 1 5 4 20 1 5 0 0 2 10
IV 0 0 1 5 1 5 0 0 1 5 0 0 0 0 2 10
VI 0 0 3 15 3 15 2 10 3 15 3 15 2 10 3 15
total 13 65 17 85 9 45 8 40 15 75 11 55 8 40 14 70
*MR=mental retardation.
tinine with GAGs concentration in 
mg/l, and the ratio was expressed 
as mg/mmol creatinine, normal 
level equals 44.6±23.7 (Less than 
2 years old), 15.3±13.0 (2-17 years 
old) and 5.2±2.5 (Adult 18-42 years 
of age).
Two dimentional electrophoresis of •	
the GAGs (2-DEP) :5 Glycosamino-
glycans (GAGs) were determined 
qualitatively by two dimentional 
electrophoresis to determine pos-
sible subtypes of mucopolysaccha-
ridoses.
The mothers of 4 studied patients • 
with different types of MPS were 
subjected to prenatal diagnosis of 
next pregnancy using amniocente-
sis.
GAGs level was determined in amniotic 
fluid by 2- DEP.6
Enzymatic assay:•	  For the available 
enzyme of the various types of MPS 
to confirm the diagnosis.7
As a comparison group 15 apparently 
normal age & sex matched children 
were included in the study.
reSultS                                                        
At  time  of  examination,  ages  of en-
rolled cases ranged between 13/12-12 
years with a mean age of 5.07+3.026 
years. On the other hand, the age of 
onset of clinical manifestations ranged 
between 6m-2years with a mean age 
1.37+1.05 years. 11 were males (55%) 
and 9 were females (45%). 
The overall consanguinity rate recorded 
in the current study was 80% (16 cas-
es). On the other hand+ve family his-
tory of  a  similarly affected relative was 
recorded in 60% (12 cases).
Table (1) Show the different clinical 
manifestations recorded among studied 
cases with different types of MPS and 
their frequency distribution. The most 
commonly detected clinical manifes-
tations were coarse facies (85%) fol-
lowed by hepatomegaly (75%), skel-
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IQ of studied patients ranged between 
34-100 with a mean value 66+0.17, 
The mean value of IQ of different MPS 
types is shown in (Table 2).
MPS Subtypes range Mean+Sd
   IH 34-38 36+0. 27
 I  IHS 60-75 68+0. 46
   IS 85
II 40-50 45+0. 24
III 35-50 40+0. 25
IV 80-100 90+0. 111
VI 90-100 95+0. 105
total 34-100 66+0.17
table 2: IQ distribution among studied patients with different MPS subtypes
table 3: Skeletal abnormalities among studied patients with different MPS subtypes. 
MPS 
subtypes
Vertebral column Joints thoracic cage 
Kyphosis kyphoscoliosis Stiffness laxity Pectus carinatum
Flaring of 
ribs
no % no % no % no % no % no %
I
IH 1 5 1 5 2 10 0 0 1 5 2 10
IHS 2 10 0 0 2 10 0 0 1 5 1 5
IS 0 0 0 0 1 5 0 0 0 0 0 0
II 1 5 0 0 2 10 0 0 0 0 2 10
III 2 10 0 0 2 10 0 0 0 0 1 5
IV 1 5 1 5 0 0 2 10 2 10 2 10
VI 3 15 0 0 3 15 0 0 1 5 2 10
total 10 50 2 10 12 60 2 10 5 25 10 50
Table (3) Shows the sketetal abnormalities among studied patients with different 
MPS subtypes and their frequency distribution. The most commonly detected skeletal 
abnormalilies were stiffness of the joints (60%) followed by kyphosis (50%), flaring 
of ribs (50%), pectus carinatum (25%), kyphoscoliosis (10%) and laxity of the joints 
(10%).
etal manifestations (70%), mental re-
tardation (65%), splenomegaly (55%), 
corneal opacity (45%), heart affection 
(40%) and inguinal or umbilical hernia 
(40%).
Results of GAGs value , 2- DEP and enzymatic assay of studied patients were shown 
in (Table 4), (Figure 1, 2, 3).
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A mother of one of studied cases with 
type III MPS was subjected to  2-DEP 
for the amniotic fluid twice (i.e. in the 
following two pregnancies),one of them 
have yielded a normal fetus. and the 
other was similarly affected.Another 
mother proved to have an affected fetus 
with MPS II .
diScuSSion                                                          
The present study enrolled 20 cases of 
clinically,biochemically and radiologi-
cally diagnosed MPS. They were cho-
sen from patients attending the Medical 
Genetic Center, Ain Shams University 
during the period of study. The com-
monest type was MPSIII          (7 pa-
tients, 35%), followed by MPSI (6 pa-
tients, 30%), MPSIV (3 patients, 15%), 
MPSII (2 patients, 10%) and MPSVI (2 
patients, 10%). No patient with MPS VII 
and IX were detected in this study. In 
another study done in Egypt by Shawky 
et al.8 type VI was the commonest type 
(33.3%), followed by MPSIII (22.2%), 
MPSIV (22.2%), MPSI (11.1%), MPSII 
(5.5%) and MPS VII (5.5%).
There were population differences 
in the frequency of different types of 
MPS; MPS II was the most common 
type in Israel (1/34,000) and MPS IV 
in Northern Ireland (1/840,000) while 
Sanfilippo syndrome type B is the most 
prevalent type in Greece and type A in 
England. The aparent rarity of MPS VII 
may be due to frequent fetal or neonatal 
lethality. It is likely that the true inci-
dence of MPS will become Known only 
when progress in therapy will make it 
desirable to institute early screening.1
The sex distribution among enrolled 
cases was 55% (11) males, 45% (9) 
females with male to female ratio of 
1.2:1. This finding goes with the well 
known fact that both sexes are equally 
affected in autosomal recessive  disor-
fig. 1: GAGs  value for MPS I MPS I H      
            MPS I HS      MPS I S
fig. 2: Normal GAGs Pattern           
            CS=Chondrioitin sulphate
CS
fig. 3: Big Dermatan Sulphate Pattern          
            DS= dermatan Sulphate  
DS
18
Profile of Egyptian Patients with Mucopolysaccharidosis
ders including all types of MPS except 
Hunter syndrome (MPS II), which is an 
X-linked recessive disorder.1
The overall consanguinity rate recorded 
in the current study was considerably 
high; 80%. Similarly Shawky et al.8  
reported a consanguinity rate of 77.1% 
among their studied sample of MPS.
Consanguinity is of special importance 
in genetic counseling of autosomal 
recessive disorders. Hafez et al.9 re-
ported a consanguinity rate of 28% and 
Temtamy et al.10 reported a consanguin-
ity rate of 36.8%, among  normal Egyp-
tians which help to accumulate deleteri-
ous genes in the families.
By definition a recessive disease, as 
all types of MPS except for MPS type 
II, requires the inheritance of a mutant 
allele at the same genetic locus from 
each parent. When the genes are rare, 
the likelihood of unrelated parents be-
ing carriers is rare. If the parents have a 
common ancestor who carried a reces-
sive gene, the likelihood that two of the 
descendents inherited the same allele 
is enhanced, which is applicable to the 
current study and other similar stud-
ies in Egypt in which consanguineous 
marriage is a long standing tradition. 
The less frequent the recessive gene, 
the stronger the likelihood that an af-
fected individual     is the product of 
a consanguineous mating. On the other 
hand, when the recessive gene is com-
mon in the population, the probability 
of two unrelated parents being carriers 
is great enough to minimize the role of 
consanguinity.2
Martyn11 stated that the eye is one of 
the most prominent organs involved in 
MPS. Prominent eyes, puffy eyelids, 
heavy eye brows and corneal clouding 
are the major manifestations recorded 
among patients with MPS. In the pres-
ent study corneal cloudiness was ob-
served in 9 cases (45%); whereas the 
other 11 cases had apparently clear cor-
neas (55%). The clear cornea was found 
in studied cases with MPS II, III. In 
agreement with the pervious findings. 
Shawky et al.8 reported that ocular af-
fection of their studied patients were re-
ported in 33.3%, corneal opacities were 
found in 16.7% (6 patients with MPS 
I, II, VI and III), progressive increase 
in intraocular pressure was found in 
5.6% (One patient with MPS I), while 
fundus examination showed early optic 
atrophy in 5.6% of patients (One patient 
with MPS II), bilateral papilloedema in 
11.1% of patients (Two patients with 
MPS VI) and pigmentray retinopathy in 
5.6% of patients (One patient with MPS 
III).
In the current study, mental retarda-
tion was found in patients with MPS 
IH, IHS, II and III while normal intel-
lect was a feature of patients with MPS 
type IV and VI. The foregoing finding 
is in accordance with the statements of 
Neufeld and Muenzer1 that profound 
mental retardation is a characteristic 
feature of MPS IH, the severe form of 
MPS II, and all subtypes of MPS III but 
normal intelligence may be retained in 
other types.
In the current study, heart affection 
was found in 40% of patients {patients 
with MPS I (25%), VI (10%) II (5%) 
and III (5%)} in the form of mitral pro-
lapse and regurge. Shawky et al.8 re-
ported that cardiac manifestations were 
found  in  11 patients of  their studied 
cases (61.1%), the mitral valve was the 
commonest affected valve; (38.9% had 
19
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thickened mitral valve and 33.3% had 
mitral regurge), pulmonary  hyperten-
sion  was  found  in  patients with  MPS 
III (11.1%), coronary narrowing in pa-
tients with MPS I and IV (11.1%). 
In MPS there is a wide spread de-
scribed skeletal deformities which are 
typically referred to as dysostosis mul-
tiplex.12 These include large skull with 
J shaped sella turicca, spatula shaped 
ribs, beaking of upper lumbar and low-
er thoracic vertebrae and pelvic dys-
plasia.2 Skeletal deformities recorded 
among enrolled cases in the current 
study included deformities of vertebral 
column, thoracic cage and joints. Ver-
tebral column involvement was in the 
form of lumbar kyphosis in 50%  and 
kyphoscoliosis in 10% while straight 
veretebral columen was detected in 
40%  especially  in  those  with  type III, 
IS. Shawky et al.8 found that kyphosis 
was the commonest vertebral column 
deformity as it was recorded in 45.9% 
of their cases while scoliosis was found 
in only 4.9% of them.
As regards joints involvement, 60% 
of cases had stiff joints, while 30% 
had normal joints and 10% who were 
diagnosed as cases of Morquio syn-
drome had lax joints. Mckusick et al.13 
stated that many joints of patients with 
Morquio syndrome, tend to be exces-
sively loose.
The thoracic cage deformities mostly 
related to the sternum were found in 
25% of enrolled cases in the current 
study. They were markedly a prominent 
feature in cases of Morquio syndrome. 
Such deformities were not present in 
cases with Hunter and Sanfilippo syn-
dromes and this goes with Benson and 
Fenson14, as they reported thoracic cage 
abnormalities in 50% of their cases with 
IH, IHS and IV types of MPS.
On the other hand, 15 out of 20 cases 
enrolled in the current study had he-
patomegaly (75%), 11 cases had sple-
nomegaly (55%) while umbilical and 
inginual hernias of variable  severity 
were detected in 8 cases (40%) and  4 
cases  (20%), respectively. For compar-
ison Shawky et al.8 found hepatomegaly 
in 67.2% and splenomegaly in 37.7%.
In the present study the patients were 
subjected to estimation of the level 
of urinary GAGs by DMB test which 
proved to be high in all cases except 
one case suspected to be MPS IV and 
another case suspected to be MPS III.
After that patients were subjected to 
2-DEP to determine the pattern of 
GAGs for probable  type of MPS. Elev-
en cases (55%) showed dermatan sul-
fate (Type I, II, VI). The 7 cases (35%) 
showed  hepran  sulphate  (Type III) 
while 2 cases (10%) showed  keratan 
sulfate (Type IV). Finally patients were 
subjected to enzyme assay specific for 
each type. Patients who showed der-
matan sulphate electrophoretic pattern 
by 2-DEP the α-L-iduronidase enzyme 
assay was done for them, 6 of them 
showed deficiency of the enzyme which 
is specific for MPSI (IH, IHS, IS). The 
two males with coarse facies,clear cor-
nea and mental retardation, enzyme 
assay of iduronate-2-sulphate which is 
specific for MPS II was done for them 
and showed 0.1 and zero level. The 
rest of cases were subjected to Aryl 
sulfatase B assay specific for MPS VI 
20
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which showed zero level. The 7 pa-
tients who showed hepran sulfate which 
is specific for MPS III were subjected 
to the available enzyme assay in our 
laboratory for MPS III B (N-Acetyl-α-
glucosaminidase) and their level ranged 
from 25-41.88 (Normal range 10-45µ 
mol/L/h), so these 3 patients with MPS 
III  belong most probably to type III A, 
C, D where the deficient enzymes can-
not be assayed in our laboratory. The 2 
cases with characteristic skeletal defor-
mity and showed keratan sulfate with 
2-DEP were subjected to assay of galac-
tose-6-sulphatase which is  specific for 
MPS IV A which showed a low level .
Prenatal diagnosis was done by 2-DEP 
of the amniotic fluid for four mothers 
of affected patients of MPS. One fetus 
proved to be affected with MPS III. An-
other fetus was affected with MPS II. 
The other fetuses were normal.
In conclusion, definitive laboratory 
diagnosis of MPS is achieved by 3 se-
quential steps, which are the quantita-
tive detection of excessive excretion of 
GAGs in  the  urine  followed by uri-
nary GAGs qualitative assay by  two 
dimensional electrophoresis (2-DEP) to 
determine possible MPS type, the elec-
trophoretic pattern of GAGs may be 
dermatan sulphate, heparan sulphate, 
and or keratan sulphate. 
Heparan sulfate is diagnostic for MPS 
III. Dermatan sulfate pattern is present 
in MPS VI. In cases with MPS I (IH, 
IHS, IS) or MPS II, the electrophoretic 
pattern of GAGs may be a big dermatan 
sulfate spot figure (3). 
So in cases of MPS I, II, VI the 2-DEP 
is not diagnostic for any of the 3 types. 
When one of these three types is sus-
pected, it is recommended first to 
carry out an enzymatic assay for α-L-
iduronidase. If it is deficient it is diag-
nostic for MPS I (IH, IHS, IS), but if 
it is of normal level, we are left with 
two other possibilities: first if the  pa-
tient is a male, has clear cornea, and 
from family history there is an  indica-
tion of X-linked recessive inheritance, 
it is recommended to conduct an assay 
of the enzyme iduronate-2-sulfatase, if 
it is deficient it is diagnostic for MPS 
II. The second possibility if the patient 
is either a male or a female with coarse 
facial features, gross corneal opacity, 
skeletal deformity, and organomegaly, 
it is recommended to do the enzymatic 
assay for aryl sulfatase B, if it is found 
to be deficient, it is diagnostic for MPS 
VI.
In cases of MPS IV, patients have char-
acteristic skeletal deformities (Pectus 
craniatum, lumbar kyphosis, enlarged 
joints, lax joints, and receded head to 
the back), it is recommended to do en-
zymatic assay for both types of MPS 
IV (Severe and mild) from the start to 
avoid misdiagnosis of MPS IV as the 
patient may have a normal GAGs level 
and may be non excretory of keratan 
sulphate.
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